Trazodone has not been linked to major birth defects, miscarriage, or other serious pregnancy complications in the available research. The FDA’s current prescribing label states that published studies over several decades have not identified drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes. That said, the total body of evidence is still smaller than what exists for more commonly studied antidepressants, so the decision involves weighing real benefits against limited but reassuring data.
What the Safety Data Shows
The largest comparative study to date, conducted through the European Network of Teratology Information Services (ENTIS), found that pregnancy outcomes in women exposed to trazodone during early pregnancy were similar to outcomes in women taking SSRIs, a class of antidepressants with decades of pregnancy safety data. Rates of major congenital anomalies and spontaneous abortion were not elevated in the trazodone group compared to the SSRI group.
The FDA maintains a pregnancy exposure registry that continues to track outcomes in women who take antidepressants while pregnant. So far, the accumulated case reports, case series, and cohort studies have not flagged any consistent pattern of harm. This is reassuring, but researchers note that larger studies are still needed to fully confirm trazodone’s reproductive safety.
How Trazodone Reaches the Baby
Trazodone does cross the placenta. In one detailed case, the drug and its active breakdown product were measured in cord blood about seven hours after the mother’s dose, and the levels were comparable to those in the mother’s bloodstream. This means the baby is exposed to meaningful amounts of the medication during pregnancy, which is why the question of safety matters and why ongoing monitoring is part of standard care.
Possible Effects on Newborns
With SSRIs and similar medications, roughly one-third of exposed newborns show some signs of neonatal adaptation syndrome: irritability, feeding difficulties, or breathing irregularities in the first hours to days after birth. Severe symptoms occur in about 3% to 13% of those cases. Whether trazodone carries the same risk is less clear because fewer babies have been studied, but at least one documented case involved a newborn with persistent breathing difficulties that required five days in the neonatal intensive care unit. The infant recovered fully and developed normally.
Clinicians could not definitively say whether trazodone caused the breathing issue in that case, partly because the mother was also taking other medications. Still, the possibility exists, and it’s something your medical team will be prepared to watch for at delivery.
Why It’s Commonly Prescribed in Pregnancy
Most pregnant women who take trazodone are using it for insomnia, not depression. At lower doses of 50 to 100 mg per day, trazodone acts primarily as a sleep aid. The median dose in the ENTIS study was 100 mg daily. This is well below the 150 to 400 mg range typically used for depression, which means the baby’s exposure is generally lower when the drug is used for sleep.
Pregnancy-related insomnia is extremely common and often dismissed as a normal part of pregnancy, but untreated sleep disorders carry their own risks. A large U.S. claims-based study found that maternal sleep disorders were independently associated with significantly higher odds of gestational diabetes (60% increased odds), gestational hypertension (60% increased), preeclampsia (70% increased), postpartum depression (more than three times higher odds), and even stillbirth (more than double the odds). These are not small numbers. The point isn’t to scare you into taking medication, but to make clear that “just toughing it out” with severe insomnia isn’t risk-free either.
How It Compares to Other Options
Sedating antihistamines are generally considered first-line sleep aids during pregnancy because they have the longest safety track record. However, evidence for how well they actually work for insomnia is limited. Trazodone appears to be a reasonable next option based on current data, particularly because its pregnancy outcomes look comparable to those of SSRIs.
SSRIs like sertraline and fluoxetine have the most extensive pregnancy safety data of any antidepressant class, with thousands of exposed pregnancies studied. Trazodone’s safety profile appears similar, but the total number of studied pregnancies is smaller. If you’re taking trazodone specifically for depression rather than sleep, your provider may discuss whether switching to a better-studied antidepressant makes sense for your situation, or whether staying on a medication that’s already working well is the lower-risk choice. Changing medications mid-pregnancy introduces its own set of concerns, including the risk of a depressive relapse.
Breastfeeding After Delivery
Trazodone passes into breast milk, but in small amounts. The milk-to-plasma ratio is about 0.14, meaning breast milk contains roughly one-seventh the concentration found in the mother’s blood. At typical intake volumes, a breastfeeding infant would be exposed to less than 0.005 mg per kilogram of body weight, compared to the mother’s dose of about 0.77 mg per kilogram. No pattern of adverse effects in breastfed infants has been identified in postmarketing reports.
Making the Decision
The choice to continue, start, or stop trazodone during pregnancy is a balancing act. On one side, the existing data is reassuring but not as robust as what’s available for some other medications. On the other, untreated insomnia and depression during pregnancy carry well-documented risks to both mother and baby, including preterm birth, low birth weight, preeclampsia, and postpartum depression. Abruptly stopping a medication that’s managing a real condition can trigger a rebound that’s worse than the original problem.
If you’re currently taking trazodone and have just found out you’re pregnant, don’t stop the medication on your own. A gradual, supervised plan is safer than an abrupt stop. Your provider can help you weigh the specific dose you’re on, what you’re taking it for, and whether alternatives with more data might be appropriate for your situation.